阿尔兹海默病试验性药物donanemab展示出微小医治愿望

2021年1月18日 讯 /100医药网BIOON/ --美国礼来制药公司近日发布了一项对于阿尔兹海默病试验性药物donanemab的小型研讨令人鼓励的成果。

图片起源：medicalxpress.com

这项为期两年的2期临床实验归入了272名轻度至中度有阿尔兹海默病症状的患者，纽约时报申报说，礼来公司表现，相比接管抚慰剂医治的患者而言，通过每周围输注这种试验性药物的患者智力降低的速率减缓了32%；当进行donanemab药物6-12个月的医治后，患者机体不会再携带β淀粉样卵白斑块，这是阿尔兹海默病发病的标记。

然而，该研讨成果今朝尚未被其他研讨职员进行审查，也并未以任何模式进行颁发，该药物的次要反作用在服用试验性单克隆抗体来医治阿尔兹海默病的患者中十分罕见，即年夜脑中呈现体液积聚，并且这种反作用会产生在近30%的患者中，但年夜多半人并不会表示出症状，仅能在脑成像中察看到这种环境。

今朝该实验成果还必要复制，来自加利福尼亚年夜学的迷信家Michael Weiner博士表现，即使如斯，阿尔兹海默病新型药物donanemab的开辟关于好多患者和家庭而言都是一年夜喜信。（100医药网100yiyao.com）

原始出处：

Drug maker Eli Lilly on Monday announced promising results from a small study of an experimental Alzheimer"大众s disease drug called donanemab.

The two-year, phase 2 clinical trial included 272 patients with mild-to-moderate Alzheimer"大众s disease symptoms. The company said that patients who received the drug by infusion every four weeks had a 32 percent slower rate of mental decline than those who were given a placebo, The New York Times reported. After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques that are hallmarks of Alzheimer disease, according to Daniel Skovronsky, M.D., the company"大众s chief scientific officer.......